Oops, you're using an old version of your browser so some of the features on this page may not be displaying properly.

MINIMAL Requirements: Google Chrome 24+Mozilla Firefox 20+Internet Explorer 11Opera 15–18Apple Safari 7SeaMonkey 2.15-2.23

Poster display session: Biomarkers, Gynaecological cancers, Haematological malignancies, Immunotherapy of cancer, New diagnostic tools, NSCLC - early stage, locally advanced & metastatic, SCLC, Thoracic malignancies, Translational research

4209 - Brain metastasis in ovarian cancer patients

Date

20 Oct 2018

Session

Poster display session: Biomarkers, Gynaecological cancers, Haematological malignancies, Immunotherapy of cancer, New diagnostic tools, NSCLC - early stage, locally advanced & metastatic, SCLC, Thoracic malignancies, Translational research

Topics

Supportive Care and Symptom Management

Tumour Site

Ovarian Cancer

Presenters

Alexandre Andre da Costa

Citation

Annals of Oncology (2018) 29 (suppl_8): viii332-viii358. 10.1093/annonc/mdy285

Authors

A.A.B.A. da Costa1, E.S. Dos Santos1, L. de Brot1, A.R.G. Ribeiro2, D.P. Cotrim2, N. Carvalho Pandolfi3, M.G. Cesca3, M.J. Chen4, G. Baiocchi5

Author affiliations

  • 1 Medical Oncology, A.C. Camargo Cancer Center, 01509-900 - Sao Paulo/BR
  • 2 Medical Oncology, A. C. Camargo Cancer Center, 01509-010 - Sao Paulo/BR
  • 3 Clinical Oncology, A. C. Camargo Cancer Center, 01509-010 - Sao Paulo/BR
  • 4 Radiation Therapy, A. C. Camargo Cancer Center, 01509-010 - Sao Paulo/BR
  • 5 Gynaecology Oncology, A. C. Camargo Cancer Center, 01509-010 - Sao Paulo/BR
More

Resources

Abstract 4209

Background

Central nervous system (CNS) metastasis is a rare event in ovarian cancer patients and current prognostic index used for other tumors do not fit for ovarian cancer patients with brain metastasis (BM). We sought to evaluate prognostic factors for overall survival (OS) in ovarian cancer patients with BM.

Methods

We retrospectively evaluated patients with diagnosis of ovarian carcinoma and BM treated at A.C. Camargo Cancer Center from January 2007 to December 2017. Clinical data from diagnosis and at the moment of diagnosis of BM were collected. OS was defined as the time from diagnosis of BM to the moment of death by any cause. OS was calculated using Kaplan Meier curves and log rank test was used to compare OS curves. Univariate cox regression was used to evaluate prognostic factors for OS.

Results

From 560 patients 26 presented BM. Median age at diagnosis of BM was 62.9 years old, 23 patients had high grade serous carcinoma, 2 had high grade endometrial carcinoma and 1 carcinosarcoma. Recurrences in the brain were classified as platinum sensitive in 14 patients (53.8%) and platinum resistant in 11 patients (42.3%), ECOG performance status was 0 or 1 in sixteen patients. Fourteen patients (53.8%) had disease progression exclusively in the CNS. The median number of BM was 4, and medium size of the largest lesion was 3.2cm. Median time from initial diagnosis to BM was 31.7 months. Eight patients were treated with surgery, 15 with whole brain radiotherapy (RT), 5 with stereotaxic RT and 4 patients received systemic treatment at the moment of BM diagnosis. Median follow up was 18.7 months and median OS was 10.8 months. Factors associated to OS were as following: platinum sensitive recurrence (HR 0.34, CI95% 0.12-0.99; p = 0.049), higher number of previous treatment lines (HR 1.57, CI95% 1.12-2.19; p = 0.008), ECOG performance status (HR 2.52, CI95% 1.24-5.09; p = 0.010), and longer interval from initial diagnosis to BM (p = 0.025). Notably, number of brain metastasis, largest tumor size and progression outside CNS were not related to survival.

Conclusions

Factors related to sensitivity to platinum therapy and BM as early event during the course of disease seem to be more related to survival than factors usually related to survival in BM from other cancers.

Clinical trial identification

Legal entity responsible for the study

A.C. Camargo Cancer Center.

Funding

Has not received any funding.

Editorial Acknowledgement

Disclosure

All authors have declared no conflicts of interest.

This site uses cookies. Some of these cookies are essential, while others help us improve your experience by providing insights into how the site is being used.

For more detailed information on the cookies we use, please check our Privacy Policy.

Customise settings
  • Necessary cookies enable core functionality. The website cannot function properly without these cookies, and you can only disable them by changing your browser preferences.